Today, Roth Capital's analyst Kyle Bauser has maintained a 'Buy' rating for SANUWAVE Health (SNWV, Financial) while raising the price target from $54.00 to $55.00.
Here is a brief overview of historical ratings for SANUWAVE Health (SNWV, Financial):
- On July 29, 2025, Roth Capital initiated coverage on SANUWAVE Health (SNWV, Financial), announcing a 'Buy' rating with a target price of $49.00.
SANUWAVE Health Inc is an ultrasound and shock wave technology company using patented systems of noninvasive, high-energy, acoustic shock waves or low-intensity and non-contact ultrasound for regenerative medicine and other applications. The company's focus is regenerative medicine utilizing noninvasive, acoustic shock waves or ultrasound to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's two primary systems are UltraMIST and PACE. UltraMIST and PACE are the only two Food and Drug Administration (FDA) approved directed energy systems for wound healing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.